Results 81 to 90 of about 3,395 (155)

Effects of Alirocumab and Evolocumab on Cardiovascular Mortality and LDL-C: Stratified According to the Baseline LDL-C Levels

Reviews in Cardiovascular Medicine
Background: A meta-analysis was conducted to determine whether the cardiovascular mortality and lipid-lowering effects of alirocumab and evolocumab are influenced by various baseline low-density lipoprotein cholesterol (LDL-C) levels.
Hui Ma, Wenfang Ma, Yang Liu, Lixing Chen, Peng Ding   +4 more
doaj   +1 more source

HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox". [PDF]

, 2016
BackgroundProprotein convertase subtilisin kexin 9 (PCSK9) inhibitors reduce low-density lipoprotein cholesterol (LDL-C) and improve outcomes in the general population.
Deeks, Steven, Ganz, Peter, Grunfeld, Carl, Hsue, Priscilla Y, Hur, Sophia, Kohli, Payal, Ma, Yifei, Scherzer, Rebecca, Scott, Rob, Wasserman, Scott, Weigel, Bernard   +10 more
core   +1 more source

Alirocumab Treatment and Achievement of Non‐High‐Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundNon‐high‐density lipoprotein cholesterol (non‐HDL‐C) and apolipoprotein (apo) B are better predictors of atherosclerotic cardiovascular disease risk than low‐density lipoprotein cholesterol alone.
Harold E. Bays, Lawrence A. Leiter, Helen M. Colhoun, Desmond Thompson, Laurence Bessac, Robert Pordy, Peter P. Toth   +6 more
doaj   +1 more source

Cardiovascularis prevenció – 2016 | Cardiovascular prevention – 2016 [PDF]

, 2016
Absztrakt A cardiovascularis betegségek jelentik világszerte a korai halálozás fő okát annak ellenére, hogy elsősorban a gazdaságilag fejlett országokban a cardiovascularis mortalitás az utóbbi ...
Szabados, Eszter, Vértes, András
core   +1 more source

The impact of the national reimbursement drug list negotiation policy on the accessibility and utilization of evolocumab and alirocumab in different levels of hospitals: an interrupted time series analysis

Frontiers in Pharmacology
ObjectiveIn December 2021, evolocumab and alirocumab were included in the National Reimbursement Drug List Negotiation (NRDLN), with implementation commencing in January 2022.
Wan Tang, Wan Tang, Wei Li, Wei Li, Anqi Zhang, Huanhuan Wu, Huanhuan Wu, Wei Lu, Wei Lu, Yan Fan, Yan Fan   +10 more
doaj   +1 more source

Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect? [PDF]

, 2017
Data from basic science experiments is overwhelmingly supportive of the causal role of immune-inflammatory response(s) at the core of atherosclerosis, and therefore the theoretical potential to manipulate the inflammatory response to prevent ...
Abbas, Agca, Ait-Oufella, Albert, Alexander, Alexander, Alexander, Alexander, Andersen, Aziz, Babelova, Bellosta, Bevilacqua, Bhaskar, Blom, Boekholdt, Boekholdt, Bostrom, Brånén, Bulgarelli, Bulgarelli, Burke, Cai, Cannon, Casas, Collins, Cronstein, Dahlman-Ghozlan, Danesh, Davenport, Davey Smith, Davidson, DeOliveira, Devlin, Dinarello, Duewell, Duivenvoorden, Eisenhardt, Elango, Elhage, Ettehad, Flood, Fraser, Freigang, Fulgoni, Galkina, Galkina, Garlanda, Grassia, Grassia, Greenberg, Hansson, Hauer, Herder, Holmes, Hu, Huang, Huber, Interleukin 1 Genetics Consortium, Ivandic, Kalliolias, Kaptoge, Kimura, Kinlay, Kirii, Kleinman, Koltsova, Kureishi, Kwak, Lee, Leite, Leite, Lewington, Liao, Libby, Libby, Macritchie, Maddaluno, Maeda, Maffia, Makheja, Margaritis, McInnes, Menu, Micha, Mihaylova, Mira, Mohler, Montezano, Mulhaupt, Murad, Myasoedova, Myung, Nakata, Nicholls, O'Donoghue, Ogdie, Ohta, Pauling, Peters, Qiao, Quarck, Rajamäki, Rastogi, Reiss, Rezaie-Majd, Ridker, Ridker, Rincón, Robertson, Romano, Rosenson, Rosenson, Roubille, Ryan, Rössig, Saeed, Sage, Sarwar, Sattar, Scalia, Schett, Schieffer, Schuett, Serruys, Sever, Sever, Shah, Shaposhnik, Singh, Sirtori, Sniderman, Soedamah-Muthu, Solomon, Southan, Souverein, Sprague, Srikakulapu, Strober, Sukovich, Swerdlow, Swirski, Talmud, Tay, Teng, Thompson, Tits, Toedter, Turunen, Tzellos, Walker, Wang, Wang, Watson, Weintraub, Welsh, Welsh, Welsh, Welsh, Weng, Wensley, White, Wilensky, Willeit, Willis, Wong, Woodward, Xanthoulea, Ye, Ye, Yilmaz, Youssef, Zalewski, Zhao   +173 more
core   +2 more sources

The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab[S]

Journal of Lipid Research, 2017
An elevated level of lipoprotein (a) [Lp(a)] is a risk factor for CVD. Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9, is reported to reduce Lp(a) levels.
Byambaa Enkhmaa, Erdembileg Anuurad, Wei Zhang, Kun Yue, Ching-Shang Li, Lars Berglund   +5 more
doaj   +1 more source

Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk [PDF]

, 2016
Therapeutic interventions that lower LDL-cholesterol effectively reduce the risk of coronary artery disease (CAD). However, statins, the most widely prescribed LDL-cholesterol lowering drugs, increase diabetes risk. We used genome-wide association study (
Asselbergs, Folkert W., Bakker, Paul I. W., Holmes, Michael V., Keating, Brendan J., Moore, Jason H., Palmer, Tom M., Swerdlow, Daniel I., Tragante, Vinicius   +7 more
core   +1 more source

Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate. [PDF]

, 2016
The most prescribed medications in the world are statins, lipid modifiers that have been available for over 25 years and amongst the most investigated of all drug classes.
Banach, Maciej, Capewell, Simon, Hobbs, FD Richard, Malhotra, Aseem, Mikhailidis, Dimitri P   +4 more
core   +1 more source

Alirocumab in Polyvascular Atherosclerotic Disease

Journal of the American College of Cardiology, 2020
Jukema et al. ([1][1]) demonstrated in a pre-specified analysis from the ODYSSEY-OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial that alirocumab was associated with absolute risk reduction (ARR) in cardiovascular ...
openaire   +2 more sources